R Paridaens
Overview
Explore the profile of R Paridaens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brouckaert O, Van Asten K, Laenen A, Soubry A, Smeets A, Nevelstreen I, et al.
Breast Cancer Res Treat
. 2017 Nov;
168(1):189-196.
PMID: 29159760
Purpose: Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between...
2.
Vulsteke C, Pfeil A, Schwenkglenks M, Pettengell R, Szucs T, Lambrechts D, et al.
Breast Cancer Res Treat
. 2014 Aug;
147(3):557-70.
PMID: 25168315
To assess the impact of patient-related factors, including genetic variability in genes involved in the metabolism of chemotherapeutic agents, on breast cancer-specific survival (BCSS) and recurrence-free interval (RFI). We selected...
3.
Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, et al.
Breast Cancer Res Treat
. 2014 May;
146(1):109-16.
PMID: 24816806
Aromatase inhibitor (AI) therapy for estrogen receptor-positive breast cancer is known to induce or enhance musculoskeletal problems. We have previously reported that loss of grip strength is more pronounced in...
4.
Dieudonne A, Lambrechts D, Smeets D, Belmans A, Wildiers H, Paridaens R, et al.
Ann Oncol
. 2013 Nov;
25(1):90-5.
PMID: 24265353
Background: Tamoxifen remains important in the treatment and prevention of estrogen receptor-positive breast cancer. In postmenopausal women, it can lead to endometrial changes such as cystic appearances, hyperplasia, polyps and...
5.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al.
Br J Cancer
. 2013 Mar;
108(4):887-900.
PMID: 23462807
Background: There are no validated markers that predict response in metastatic renal cell cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide polymorphisms (SNPs) that...
6.
Vulsteke C, Lambrechts D, Dieudonne A, Hatse S, Brouwers B, Van Brussel T, et al.
Ann Oncol
. 2013 Feb;
24(6):1513-25.
PMID: 23396606
Background: To assess the impact of single-nucleotide polymorphisms (SNPs) on predefined severe adverse events in breast cancer (BC) patients receiving (neo-)adjuvant 5-fluorouracil (FU), epirubicin and cyclophosphamide (FEC) chemotherapy. Patients And...
7.
Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al.
Br J Cancer
. 2012 Nov;
107(10):1665-71.
PMID: 23132391
Background: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without...
8.
Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, et al.
Ann Oncol
. 2012 Oct;
24(2):350-355.
PMID: 23038762
Background: Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention...
9.
Fontein D, Houtsma D, Hille E, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, et al.
Ann Oncol
. 2012 Aug;
23(12):3091-3097.
PMID: 22865782
Background: Many adverse events (AEs) associated with aromatase inhibitors (AIs) involve symptoms related to the depletion of circulating estrogens, and may be related to efficacy. We assessed the relationship between...
10.
Paridaens R, Rixe O, Pinel M, Wildiers H, Zorza G, Ferre P, et al.
Cancer Chemother Pharmacol
. 2012 Aug;
70(4):503-11.
PMID: 22864874
Objective: To determine the recommended dose (RD) of vinflunine in combination with trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and to investigate potential pharmacokinetic...